key: cord-0868890-xhpo1e9f
authors: Lipworth, Brian; Kuo, Chris RuiWen; Lipworth, Samuel; Chan, Rory
title: Inhaled Corticosteroids and COVID-19
date: 2020-09-15
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.202005-2000le
sha: 2967b956dcc6eb346331ed612bf68d4286e51106
doc_id: 868890
cord_uid: xhpo1e9f

nan

To the Editor:

Maes and colleagues (1) present data from lung tissue that showed that mRNA expression for ACE2 (angiotensin-converting enzyme 2) was significantly greater in 38 patients with moderate chronic obstructive pulmonary disease (COPD) compared with 61 healthy control subjects but not compared with a group of 7 patients with asthma or asthma-COPD overlap syndrome. Furthermore, values for ACE2 expression in a heterogeneous group of 23 patients with obstructive airway disease (OAD) comprising COPD, asthma-COPD overlap syndrome, or asthma not receiving inhaled corticosteroids (ICS) were significantly higher than values in 56 control subjects but not values in 25 patients with OAD receiving ICS. The problem with interpreting these results in a heterogeneous group of patients with OAD is that ACE2 is upregulated in smokers and in those with COPD but is downregulated in those with asthma and those with atopy (2, 3). Furthermore, assaying ACE2 mRNA only tells one-half of the story with regard to entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into lung tissue, as asthma and atopy are both associated with upregulation of TMPRSS2 (transmembrane protease serine 2) in airway epithelial cells (3) . In this regard, in induced sputum cells from asthma patients, ICS have been shown to exhibit suppressive effects ex vivo on both ACE2 and TMPRSS2 expression (4). Maes and colleagues (1) fail to point out the inhibitory in vitro effects of ICS on local and systemic production of IL-6 (5, 6), this being the strongest predictor for impending respiratory failure in severe coronavirus disease (COVID-19) (7) . Finally, a more specific suppressive effect from ICS on SARS-CoV-2 replication has been described with ciclesonide and mometasone furoate but not with budesonide, beclomethasone, or fluticasone (8) .

We believe that, taken together, these observations reinforce the need for patients with eosinophilic asthma and COPD to continue receiving their controller therapy containing ICS, as that will provide optimal disease control and perhaps also confer protection against viral triggers, perhaps including SARS-CoV-2. n Reply to Lipworth et al.

We totally agree with the letter by Lipworth and colleagues in response to our editorial emphasizing that patients with asthma need to continue using their inhaled corticosteroid (ICS)containing controller therapy during the coronavirus disease (COVID-19) pandemic, as this provides optimal asthma control and also confers some protection against viral triggers, perhaps including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). They also highlight several interesting papers, published after the publication of our editorial, which address two key research questions: 1) are subjects with asthma at increased risk of COVID-19 infection and related illness? and 2) does ICS use modulate this risk? Because asthma is a very heterogeneous disease, we hypothesize that asthma phenotypes and the type of underlying airway and systemic inflammation need to be taken into account to answer these questions correctly (see Table 1 ).

In children with asthma, allergic sensitization and other type 2 biomarkers (such as fractional exhaled nitric oxide and epithelial expression of IL-13, which increases the expression of inducible nitric oxide synthase) were inversely related to ACE2 (angiotensin-converting enzyme 2), the cellular receptor for SARS-CoV-2 (2). Moreover, in ICS-naive adults with mild allergic asthma, segmental allergen bronchoprovocation significantly reduced ACE2 expression in the bronchial epithelium. In contrast, nonatopic asthma was not associated with reduced ACE2 expression, which is in line with the findings by Peters and colleagues (3), demonstrating no difference in ACE2 gene expression in induced sputum of subjects of the SARP-3 (Severe Asthma Research Program-3) as compared with healthy control subjects, as atopy is less prevalent in adults with severe asthma. In addition, in samples from bronchial brushes and biopsies, there were similar levels of ACE2 mRNA expression in healthy volunteers and adult subjects with mild-to-moderate asthma or 

COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells

COVID-19-related genes in sputum cells in asthma: relationship to demographic features and corticosteroids

Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15